JACOBIO-B News

Gacos (01167) was approved for the third phase of the joint trial of the two core projects and received consecutive brokerage buying ratings

Zhitong FinanceFeb 19 17:42

Gacos-B (01167.HK): Golerese second-line pancreatic cancer data, best-in-class focus, first-line non-minor data update

太平洋證券Jan 29 00:00

Gacos Golerese's pancreatic cancer data surpassed similar Tianfeng Securities's target price of HK$7.68

Gelonghui FinanceJan 21 09:34

Gacos-B (01167.HK): Small Molecule Innovative Drug Dark Horse Breaks Through Undrugable Targets

天風證券Jan 17 07:36

Gacos-B (1167.HK): Grarese's three indications are rapidly advancing, focusing on ESMO's exclusive joint use data

太平洋證券Sep 4, 2023 00:00

Gacos (1167.HK) 2023 Interim Report Review: Specializing in difficult drug targets, similar products lead the world in progress

西部證券Sep 1, 2023 00:00

Changes in Hong Kong stocks | Gacoth-B (01167) fell more than 15% and fell more than 36% in the past two days, and CICC lowered its target price by 23.2% to HK$8.3

Zhitong FinanceJul 6, 2023 14:58

Gacos-B (01167.HK): The core catalyst clearly focuses on ASCO and ESMO data updates

中郵證券Mar 27, 2023 16:07

Gacos-B (01167.HK): Core Pipeline Advances Smooth, Innovative Target Drugs Highlight R&D Strength

中金公司Mar 24, 2023 16:07

Garcosis-B (01167.HK): KRAS and SHP2 are about to break through global innovation targets

國金證券Mar 23, 2023 08:33

Gacos (01167.HK): Break through untreatable targets and focus on making innovative FIC/BIC drugs

西部證券Feb 21, 2023 00:00

Garcosis-B (1167.HK): Global leader in core projects KRAS G12CI is expected to be the first in China

嘉謨證券Feb 13, 2023 00:00

Garcosis-B (01167.HK): An innovation engine focused on oncolog-targeted drugs

中郵證券Dec 12, 2022 00:00

Garcos-B (01167.HK): KRAS G12C inhibitor critical clinical approval for development

國金證券Sep 7, 2022 00:00

Gacos (01167.HK) 2022 Interim Report Review: Research Pipeline Continues to Advance to Build No. 1 KRAS Subdivision Circuit

西部證券Sep 6, 2022 00:00

Garcosis-B (01167.HK): Core products are progressing smoothly, follow the reading of product lung cancer data

中金公司Aug 25, 2022 09:11

Garcosis-B (01167.HK): Clinical promotion of combined use development of difficult drug targets is worth looking forward to

國金證券Aug 23, 2022 00:00

Garcos-B (1167.HK) 2021 performance review: Global SHP2 inhibitor leader is progressing smoothly in research pipeline

西部證券Mar 28, 2022 14:42

Gacos-B (01167.HK): CD73 monoclonal antibody clinically approved SHP2, leading the development progress of KRAS

國金證券Mar 26, 2022 00:00

Garcos-B (01167.HK): SHP2 inhibitors are progressing smoothly and strategically investing in NK cell therapy

中金公司Mar 23, 2022 00:00